It has subsequently been shown that the metabolite thus formed, 25-hydroxyvitamin D (250HD) is the major circulating metabolite of vitamin D; the major active metabolite, 1,25-dihydroxyvitamin D3 is formed by lahydroxylation of 250HD, this step occurring almost exclusively in the kidney.2 Although diet was formerly believed to be the major source of vitamin D in man it has been shown, both in the UK and North America, that endogenous skin synthesis is quantitatively the most important source,3 4 cholecalciferol (vitamin D3) being produced from the precursor 7-dehydrocholesterol in the presence of ultraviolet irradiation. 5 After the demonstration that 25-hydroxylation occurred in the liver many groups, both in Europe and North America reported low serum or plasma 250HD concentrations in patients with chronic cholestatic, alcoholic and other forms of liver disease.f22 The pathogenesis of this vitamin D deficiency aroused considerable controversy. Whilst impaired hepatic metabolism of vitamin D was an obvious possibility, -other causes such as reduced exposure to ultraviolet irradiation, low dietary vitamin D intake, impaired cutaneous synthesis of vitamin D3 caused by jaundice and malabsorption of vitamin D also required investigation.
Hepatic production of vitamin D
Hepatic production of vitamin D in man has been studied mainly by measurement of the serum 250HD response to vitamin D adnministration, using either unlabelled or radioactive vitamin D. The former studies have often involved administration of pharmacological doses of vitamin D and the results obtained may thus not be of physiological significance although they are relevant when considered in the light of vitamin D therapy. Radiolabelled vitamin D studies, in most of which the vitamin is injected as an intravenous bolus, have also to be interpreted with some caution as both the rate of delivery of the vitamin to the circulation and the form in which it is delivered are unphysiological. The appearance of 250HD in plasma after vitamin D administration reflects hepatic uptake and hydroxylation of the vitamin together with hepatic release and metabolism of the metabolite, so that these investigations do not directly measure 25-hydroxylation of 250HD. In addition, changes in serum 250HD levels after oral vitamin D will be affected by absorption of the vitamin from the intestine.
Early evidence for impaired hepatic production of 250HD in liver disease was reported by Hepner et al,23 who showed an impaired serum 250HD response to parenteral vitamin D in 27 patients with alcoholic cirrhosis; however, in three patients with primary biliary cirrhosis, a normal response was seen. Wagonfeld et a17 found no significant rise in serum 250HD levels after large doses of oral or subcutaneous vitamin D in patients with primary biliary cirrhosis; however, these results could also be explained on the basis of poor intestinal absorption and low bioavailability respectively of the vitamin. In contrast, Skinner et al, 24 showed that if provided with sufficient vitamin D, patients with severe chronic cholestatic liver disease could achieve normal serum 250HD levels; this is confirmed by the finding by several other groups of normal serum 250HD levels in vitamin D-treated patients with liver disease. 4 Quantitative computerised tomography is particularly well suited for measurements in vertebral trabecular bone, although it can also be used at other skeletal sites. Dual photon absorptiometry can also measure bone mineral content in appendicular or axial skeleton but unlike quantitative computerised tomography is unable to select out trabecular bone in the spine, where it measures combined cortical and trabecular bone mineral content together with any extravertebral mineral present in the area of measurement. The method is most commonly applied to the lumbar spine and femoral neck. Neutron activation analysis can measure either total or partial body calcium; partial body neutron activation analysis can be applied to a number of skeletal sites including the spine, hand, and forearm. The advent of these techniques over the past few years invites reconsideration of the definition of osteoporosis. Its definition as a condition in which fracture has occurred will exclude many patients with abnormally low bone mineral content who may develop osteoporotic fractures in the future and who are most likely to benefit from treatment. Providing that adequate control data are available, osteoporosis is better defined as a condition in which bone mineral content at clinically relevant skeletal sites is greater than 2 standard deviations below the control mean value, matched for age, sex and, where relevant, number of years after menopause.
From the above discussion it is clear that if a diagnosis of osteoporosis is based on vertebral fractures or loss of vertebral height the true prevalence of pathological bone loss will be underestimated. In addition, trabecular bone volume measurements in iliac crest biopsies are not necessarily representative of the clinically relevant sites; indeed, the iliac crest trabecular bone volume may be normal in patients with osteoporotic fracture.17 Studies utilising metacarpal morphometry or single photon absorptiometry of the radius have provided valuable data on cortical bone loss but this information cannot be freely extrapolated to other skeletal sites, least of all vertebral trabecular bone.
OSTEOMALACIA
Osteomalacia is characterised by defective mineralisation of bone and is essentially a histological diagnosis. The commonest symptom is bone pain; in more advanced cases, bone tenderness, proximal muscle weakness and fracture may occur. The classical biochemical changes of hypocalcaemia, hypophosphataemia and raised plasma alkaline phosphatase are not uniformly reliable indicators of bone disease and symptomatic, histologically proven osteomalacia has been documented in patients with normal plasma biochemistry.55 56 Plasma alkaline phosphatase is the most accurate indicator of bone disease in patients with normal liver function57 but is obviously of much less value in patients with liver disease unless the contribution to total enzyme activity made by bone and liver isoenzymes can be accurately assessed. The radiological changes of pseudofracture and pathological fractures generally occur late in osteomalacia and may be absent even in severe cases. Examination of bone histology provides the only accurate method of diagnosis; as the histological changes of osteomalacia are distributed throughout the skeleton, biopsy at a single site is representative and in practice the iliac crest is chosen.
Histologically, osteomalacia is associated with an increase in the amount of osteoid or unmineralised bone but this may also be seen in a variety of other metabolic bone disorders. The cardinal feature of osteomalacia is defective mineralisation and proper documentation of this requires the use of double tetracycline labelling.58 Tetracyclines are taken up at the mineralisation front in bone and can be visualised by fluorescence microscopy. The use of a double, time-spaced tetracycline label, given orally to the patient before the biopsy, allows examination both of the linear extent of mineralisation and its rate, from which in turn, bone formation rates at tissue and cellular level can be calculated.59 Rigorous diagnostic criteria for osteomalacia, which should be used in prevalence studies, are as follows: -(1) increased osteoid seam width; (2) prolonged osteoid maturation period (calculated from osteoid seam width and bone formation rate at cellular level), and (3) reduced mineralisation rate.60 In the absence of tetracycline labelling, an increase in osteoid amount together with reduced calcification fronts, as demonstrated by stains such as toluidine blue,6' comprise the absolute minimum criteria. As in the case of osteoporosis, control data are of prime importance and should ideally be derived from the same geographical area as the patient population. Unlike the techniques available for measuring bone mineral content, bone histomorphometry is associated with a considerable total measurement variance62-4 and small differences between control and patient populations, especially where control data from other laboratories are used, may be because of methodological or systematic interobserver differences rather than reflecting true differences between the two groups.
Estimates of the prevalence of osteomalacia in chronic cholestatic liver disease range between 0 and 72% 13 15 17 20 47 65-72 This enormous variation reflects several factors. First, few of the reported studies have been unselected, secondly, the severity of liver disease in the patients studied has varied, and thirdly, histological criteria for the diagnosis of osteomalacia have differed. Although reports of osteomalacia associated with chronic liver disease have appeared in the literature for many years,7376 histological confirmation had to await techniques for cutting undecalcified sections of bone77 and for demonstrating calcification fronts in bone.58 61 and heavy tobacco consumption' 6 may all play a role. In addition, the higher risk of trauma in alcoholics clearly contributes to the increased fracture incidence.
Stellon et al109 have recently studied the prevalence of osteoporosis in 36 unselected patients with chronic active hepatitis, maintained on corticosteroids, using measurements of trabecular bone volume and cortical thickness in iliac crest biopsies together with metacarpal morphometry and single photon absorptiometry of the radius. Forty seven per cent were found to have cortical and/or trabecular osteoporosis, bone loss in the iliac crest showing a weak inverse correlation with the total dose of steroids; in contrast the presence of cirrhosis was not related to the degree of bone loss at any of the sites studied.
TREATMENT OF OSTEOPOROSIS IN CHRONIC LIVER DISEASE
Very little is known about the treatment of hepatic osteoporosis. Oestrogens, which are effective in preventing postmenopausal bone loss, are generally regarded as contraindicated in chronic cholestatic liver disease, as are anabolic steroids. Fluoride therapy, effective in some patients with postmenopausal or senile osteoporosis, is not specifically contraindicated in liver disease, but no trials of its use in hepatic osteoporosis have been reported.
The small amount of data available relate to the use of calcium and vitamin D therapy. Evidence for,7 47 and against69 70 a protective effect of vitamin D or its metabolites on bone loss in chronic liver disease has been claimed, these studies being based on measurements of trabecular bone volume in iliac crest biopsies and/or bone mineral content in the radius. The length of the treatment period before reassessment, however, has been too short in all these studies for accurate determination of the long term effects of treatment on bone mass'12 and no study has examined the effects of such treatment on spinal trabecular bone mineral content. The use of calcium supplements has also been advocated in hepatic osteoporosis; calcium infusions were reported to produce subjective relief of bone pain in 14 patients with primary biliary cirrhosis68 and Epstein et al122 produced more objective evidence with the demonstration that metacarpal cortical bone loss in women with primary biliary cirrhosis could be prevented with either calcium gluconate or hydroxyapatite.
PATHOPHYSIOLOGY OF OSTEOPOROSIS ASSOCIATED WITH CHRONIC LIVER DISEASE
Osteoporosis may result from either a high or low turnover state. In the former, bone formation is normal or increased, but is exceeded by resorption, whereas in low turnover osteoporosis, bone formation is reduced. This classification bears important therapeutic implications, as therapy would be aimed primarily at reducing resorption in high turnover disease, but at stimulating bone formation in low turnover states.
Reduced osteoid volume and surface extent have been shown in several studies of patients with chronic cholestatic liver disease47 69 70 72 and, where reported, the mean osteoid seam width has also been reduced.70 72 Osteoid seam width depends on three factors; first, the rate of matrix synthesis, secondly, the osteoid maturation period and thirdly the mineral appositional rate. In the presence of the prolonged osteoid maturation period72 and normal or low mineral appositional rate47 69 In this study, the mean wall thickness, or the thickness of the completed bone remodelling unit, was also shown to be reduced in the patient group, a further indication of impaired bone formation. As sigmaf, the bone formation period, was normal or increased, impaired function of osteoblasts rather than a reduction in their life span is likely to be responsible. The evidence regarding bone resorption in chronic cholestatic liver disease is more conflicting. Two studies have shown a modest increase in the surface extent of resorption47 126; this does not necessarily imply an increase in resorption rate but might simply reflect impaired bone formation at the resorption sites, as formation always follows resorption in the normal sequence of bone remodelling. The observation in both studies that despite increased surface extent of resorption cavities, osteoclasts were sparse, would favour this explanation. In addition, biochemical indicators of increased resorption such as raised serum immunoreactive parathyroid hormone levels and increased urinary hydroxyproline and calcium excretion have been absent in the majority of patients studied.47 69 70 The demonstration by Cuthbert et al, 47 however, that resorption surfaces and serum immunoreactive parathyroid hormone levels fell after six months of vitamin D therapy would support the opposite view, namely that active bone resorption is increased.
The Figure illustrates the postulated chain of events in osteoporosis associated with chronic cholestatic liver disease. Osteoblasts are believed to be responsible for matrix synthesis, maturation and mineralisation. It is suggested that their function is selectively impaired so that matrix synthesis is affected to a much greater extent than maturation or mineralisation. Decreased bone formation results in reduced mean wall and trabecular plate thickness'26 and hence to a reduced trabecular bone volume. The possible role of increased bone resorption requires further investigation; studies using recently described methods to measure resorption cavity depths127 should help to resolve this issue. Because the trabecular plate density remains normal,'26 however, erosion of whole trabecular plates does not appear to contribute to bone loss.
A recent study of bone histomorphometry in alcoholic liver disease'08 describes rather different findings. In contrast with chronic cholestatic liver disease, resorption surfaces were significantly reduced whilst osteoid seam width, mineral appositional rate and osteoid maturation period were normal. Bone formation rate and mean wall thickness were, however, reduced as in chronic cholestatic liver disease. The authors conclude that alcoholic liver disease is associated with low bone turnover and suggest that whilst the efficiency of osteoblasts is normal, as evidenced by the normal mineral appositional rate, there is a reduction in their life span resulting in reduced mean wall thickness. Measurement of the bone formation period, sigmaf, would be required to confirm this theory. This report raises the interesting possibility that the pathophysiology of bone disease in alcoholic liver disease may differ from that seen in chronic cholestatic liver disease.
Conclusions
Privational factors are probably mainly responsible for the increased prevalence of vitamin D deficiency in patients with chronic liver disease.
Although malabsorption of dietary vitamin D and 250HD has also been shown, this is unlikely to be an important pathogenetic factor except in those patients with reduced endogenous synthesis of the vitamin. Other factors such as increased urinary losses of vitamin D and cholestyramine therapy may contribute to vitamin D deficiency in chronic cholestatic liver disease. There is little evidence for any significant impairment of hepatic 250HD production in chronic cholestatic liver disease; in alcoholic liver disease, the evidence is more conflicting. Most evidence supports the view that formation of the dihydroxylated metabolites, 1,25 and 24,25(OH)2D3 is normal.
In the past, controversy over the prevalence of osteomalacia in chronic liver disease has arisen largely because of the use of inadequate histological criteria for its diagnosis and, in particular, failure to assess bone mineralisation. Early reports of a high prevalence have been disproved by subsequent studies in which more rigorous criteria have been used. There is no doubt that osteomalacia does occur in association with chronic liver disease, but its prevalence is low. Virtually all reported cases come from the UK, only one report coming from North America18; this supports the concept that privational vitamin D deficiency is an important pathogenetic factor in the development of hepatic osteomalacia, as the availability of ultraviolet irradiation in the UK is considerably less than in North America. The most recent studies from the UK indicate that the prevalence of osteomalacia is falling,72 probably reflecting the changing clinical spectrum of primary biliary cirrhosis. 128 Those patients most at risk appear to be jaundiced patients with chronic cholestatic liver disease; however, osteomalacia has also been reported in patients with alcoholic liver disease and chronic active hepatitis. '1 1310 In view of the low prevalence of osteomalacia in chronic liver disease, routine vitamin D prophylaxis seems unwarranted. Prophylaxis may however, be indicated in high risk patients with severe prolonged cholestasis, and reduced exposure to ultraviolet irradiation. For these patients and for those with documented osteomalacia, oral doses of between 400 and 4000 IU are probably adequate in most cases21; these doses are much less likely to be associated with hypercalcaemia than the high dose parenteral therapy which has traditionally been advocated.
The investigation of osteoporosis has been revolutionised over the past few years by the development of techniques which accurately measure bone mineral content in clinically relevant skeletal sites. No large study in patients with chronic liver disease has yet been reported using these techniques; however, because prevalence rates of around 30% have been reported for both cortical and trabecular osteoporosis using relatively insensitive diagnostic techniques, it seems likely that osteoporosis will emerge as a major complication of chronic liver disease. Vertebral crush fractures appear to be the most common clinical complication of osteoporosis associated with chronic liver disease and thus measurements of spinal trabecular bone mineral content will be of particular interest.
The pathogenesis of osteoporosis in patients with chronic liver disease has received little attention. Calcium malabsorption, vitamin D deficiency with secondary hyperparathyroidism, alcohol and corticosteroid therapy129 130 are all possible factors; in addition, oestrogen deficiency will contribute in peri-and postmenopausal women. The pathophysiological basis of the osteoporosis appears to be osteoblastic dysfunction rather than excessive bone resorption.
The prevention and treatment of osteoporosis in patients with chronic liver disease pose many problems, partly because these topics have been so little studied and partly because oestrogens, known to be effective in preventing postmenopausal bone loss, are contraindicated in many patients with liver disease, as are anabolic steroids. Calcium supplementation reduces cortical bone loss in chronic cholestatic liver disease'22 but its effect on vertebral trabecular bone or on cortical and trabecular bone loss in the femoral neck is unknown. Fluoride therapy has not been evaluated. With the increasing availability of techniques such as quantitative computerised tomography and dual photon absorptiometry accurate documentation of the effects of agents on bone loss in chronic liver disease has become a practical possibility and provides an important area for research in the future. The choice of therapy is difficult, but fluoride is a possible candidate and calcium supplements deserve further investigation. Oestrogen therapy should also be evaluated in suitable patients; hepatic toxicity may be reduced by the use of oestrogen implants or transdermal administration, although the effect of these preparations on spinal trabecular bone loss in the normal population has not been documented. Once effective therapies have been established, prophylaxis may well be indicated in high risk patient groups -for example, those with corticosteroid treated chronic active hepatitis and postmenopausal women with primary biliary cirrhosis.
